Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of cefpodoxime proxetil powder in China. Welcome to wholesale bulk high quality cefpodoxime proxetil powder for sale here from our factory. Good service and reasonable price are available.
Cefpodoxime proxetil powder is an oral third-generation cephalosporin antibiotic raw material. As a precursor drug, it is designed to significantly enhance bioavailability. The characteristics and grade of this powder form are strictly determined based on its medical application. It is usually presented as fine white to off-white crystalline or amorphous powder. In terms of chemical structure, by introducing a tert-pentyl oxymethyl ester at the carboxyl group of the active parent nucleus Cefpodoxime, it greatly improves the lipid solubility and intestinal absorption rate of the drug.
After oral administration, the ester bond is rapidly hydrolyzed by esterase in the gastrointestinal tract and blood, releasing the original Cefpodoxime active ingredient with strong antibacterial activity. This active ingredient exhibits broad-spectrum antibacterial effects by efficiently inhibiting the synthesis of bacterial cell wall mucopolysaccharides, and is the key starting material for preparing corresponding preparations to treat infections in the respiratory tract, urinary system, and skin and soft tissues.
Additional information of chemical compound:
| Product Name | Cefpodoxime Proxetil Powder | Cefpodoxime Proxetil Tablets | Cefpodoxime Proxetil Liquid | Cefpodoxime Proxetil Capsules |
| Product Type | Powder | Tablets | Liquid | Capsules |
| Product Purity | ≥99% | ≥99% | ≥99% | ≥99% |
| Product Specifications | Customizable | Customizable | Customizable | Customizable |
| Product Package | Customizable | Customizable | Customizable | Customizable |
Our product form
Cefpodoxime Proxetil COA
 |
||
Certificate of Analysis |
||
|
Compound name |
Cefpodoxime Proxetil | |
|
CAS No. |
87239-81-4 | |
|
Grade |
Pharmaceutical grade | |
|
Quantity |
Customized | |
|
Packaging standard |
Customized | |
| Manufacturer | Shaanxi BLOOM TECH Co., Ltd | |
|
Lot No. |
202601090056 | |
|
MFG |
Jan 9th 2026 | |
|
EXP |
Jan 8th 2029 | |
|
Structure |
|
|
| TEST STANDARD | GB/T24768-2009 Industry. Stnndard | |
|
Item |
Enterprise standard |
Analysis result |
|
Appearance |
White or almost white powder |
Conformed |
|
Water content |
≤4.5% |
0.30% |
| Loss on drying |
≤1.0% |
0.15% |
|
Heavy Metals |
Pb≤0.5ppm |
N.D. |
|
As≤0.5ppm |
N.D. | |
|
Hg≤0.5ppm |
N.D. | |
|
Cd≤0.5ppm |
N.D. | |
|
Purity (HPLC) |
≥99.0% |
99.5% |
|
Single impurity |
<0.8% |
0.48% |
|
Total microbial count |
≤750cfu/g |
80 |
|
E. Coli |
≤2MPN/g |
N.D. |
|
Salmonella |
N.D. | N.D. |
|
Ethanol (by GC) |
≤5000ppm |
400ppm |
|
Storage |
Store in a sealed, dark and dry place at -20 degrees |
|
|
|
||
|
|
||
| Chemical Formula | C21H27N5O9S2 |
| Exact Mass | 557.13 |
| Molecular Weight | 557.59 |
| m/z | 557.13 (100.0%), 558.13 (22.7%), 559.12 (9.0%), 559.13 (2.5%), 560.12 (2.1%), 559.13 (1.8%), 558.12 (1.8%), 558.12 (1.6%) |
| Elemental Analysis | C, 45.24; H, 4.88; N, 12.56; O, 25.82; S, 11.50 |
Otitis media
In addition to the acute otitis media mentioned above, for some cases of acute exacerbation of chronic otitis media, cefpodoxime proxetil powder can also exert antibacterial effects, reduce inflammation of the middle ear mucosa, improve hearing, and reduce symptoms such as ear canal discharge. In the treatment of chronic otitis media, this medication can be used in combination with other treatment methods such as ear irrigation and local medication to improve treatment effectiveness.
Paranasal sinusitis
Including acute sinusitis and acute exacerbation of chronic sinusitis. Patients often experience symptoms such as nasal congestion, purulent discharge, headache, and decreased sense of smell. Cefotaxime ester dry suspension can be used to treat bacterial infections that cause sinusitis, promote the discharge of pus from the sinuses, reduce inflammation of the sinus mucosa, and alleviate symptoms. For patients with chronic sinusitis, long-term use of this medication for preventive treatment can reduce the frequency of acute attacks.
Acute simple gonococcal cervicitis
Acute simple gonococcal cervicitis is a cervical inflammation caused by Neisseria gonorrhoeae. Patients may experience increased vaginal discharge, purulent appearance, accompanied by odor, and sometimes symptoms such as painful intercourse and bleeding. Cefotaxime ester dry suspension has good antibacterial activity against Neisseria gonorrhoeae and can effectively treat acute simple gonococcal cervicitis, eliminate pathogens, and alleviate symptoms. During the treatment process, sexual partners should be treated simultaneously to prevent cross infection.
Perianal periarthritis caused by Neisseria gonorrhoeae
When Neisseria gonorrhoeae infects the perianal skin and mucosa, it can cause perianal inflammation, and patients may experience symptoms such as redness, pain, and itching around the anus, sometimes accompanied by purulent discharge. Cefotaxime ester dry suspension can kill Neisseria gonorrhoeae, control perianal infection, alleviate symptoms, and promote healing. During treatment, attention should be paid to maintaining cleanliness and hygiene around the anus to avoid scratching.
Application in Bacterial Infections of Skin and Soft Tissues
Cefpodoxime proxetil powder is an oral third-generation cephalosporin prodrug. After oral administration, it undergoes intestinal metabolism to produce active cefpodoxime, which exhibits stable antibacterial activity against most pathogenic bacteria responsible for skin and soft tissue infections. This API powder serves as the core raw material for oral anti-infective preparations.
It is effective against common cutaneous pathogens including Staphylococcus aureus, Streptococcus pyogenes, and Staphylococcus epidermidis. Resistant to β-lactamases produced by most strains, it is indicated for mild-to-moderate bacterial skin lesions.
Clinically applicable conditions include primary folliculitis, cellulitis, secondary infections of superficial wounds, suppurative skin abrasions, hidradenitis, and mild erysipelas.Tablets and dry suspensions formulated from this powder are suitable for outpatients with mild conditions, eliminating the need for intravenous infusion and delivering superior patient compliance.
For traumatic wound infections, oral administration achieves bacteriostatic concentrations in subcutaneous tissues via systemic circulation, suppressing bacterial proliferation and alleviating inflammatory manifestations such as redness, swelling, exudation and pain. It can act as an alternative therapeutic option for skin infection strains with mild penicillin resistance; however, it shows no significant efficacy against methicillin-resistant Staphylococcus aureus (MRSA). Severe deep abscesses require adjunctive surgical debridement.
Cefpodoxime Proxetil is an important oral cephalosporin drug, and there are various methods for synthesizing its powder form. Each method has its own unique reaction pathway, condition optimization, and quality control points. The following are several common synthesis methods and their detailed descriptions:
Classical chemical synthesis method
1. Introduction of starting materials and side chains
Starting material: 7-Aminocephalosporanic acid (7-ACA) is used as the starting material, which contains a β - lactam ring and an amino group in its structure, making it easy for subsequent modification.
Side chain introduction: The side chain is connected to the 7-amino group of 7-ACA through the acylation reaction of MAEM ((S) - benzothiazol-2-yl - (2-amino-4-thiazolyl) (methoxyimino) thioacetate).
This step needs to be carried out at low temperature (0-5 ℃), using dichloromethane or N, N-dimethylformamide as solvents, triethylamine or DIPEA as base catalysts, and a reaction time of about 2-4 hours. This reaction proceeds through a nucleophilic substitution mechanism to generate the intermediate cefpodoxime acid.
2. Carboxyl esterification
Esterification reagent: IPOC (1- (isopropoxycarbonyloxy) ethyl) is used to esterify the 4-carboxyl group of cefpodoxime acid to enhance its lipid solubility and oral absorption.
Esterification conditions: In anhydrous acetonitrile, IPOC-I (1-iodoethylisopropyl carbonate) and potassium carbonate are added as bases, and the reaction is carried out at 40-50 ℃ for 6-8 hours. This process occurs through a substitution mechanism, forming carbonate bonds and releasing potassium iodide byproducts.
3. Removal of protective groups
Protective group: Chloroacetamide group is often introduced as a temporary protective group in the synthesis of cefuroxime axetil, which ultimately needs to be removed by thiourea lysis.
Removal conditions: Add excess thiourea to DMA (N, N-dimethylacetamide) and react at 60-70 ℃ for 3-5 hours. Thiourea attacks the carbon chlorine bond of chloroacetamide, producing thioacetamide and hydrogen chloride, the latter of which is neutralized by thiourea.
4. Crystallization purification and drying
Crystallization conditions: After the reaction is complete, crystallization can be induced by adding an anti solvent or by using a mixed solvent for recrystallization to improve purity.
Drying conditions: Dry the wet cefpodoxime proxetil powder under vacuum conditions at a suitable temperature (such as 40 ℃) until the moisture content meets the requirements of the pharmacopoeia.
Exploration of Green Synthesis Route
1. Enzymatic esterification
Catalyst selection: Use immobilized lipase (such as CALB) instead of traditional chemical bases to catalyze the esterification reaction of cefpodoxime acid and IPOC.
Reaction conditions: Add immobilized CALB in a mixture of tert butanol and water solvent, and control the temperature and rotation speed for the reaction. Enzymatic catalysis has high selectivity, can avoid side reactions, and can be recycled to reduce costs.
2. Ionic liquid system
Solvent selection: Use ionic liquids (such as [BMIM] PF ₆) instead of traditional organic solvents to achieve a one pot reaction of MAEM acylation and esterification.
Reaction advantages: Ionic liquids have good solubility and thermal stability, can reduce solvent usage, and can be reused. The one pot method simplifies the process flow and improves the yield.
Process optimization and quality assurance
1. Key parameter control
Temperature control: Each step of the reaction requires strict temperature control to ensure smooth progress and avoid side reactions. For example, MAEM acylation requires low temperature to prevent hydrolysis, while esterification reaction requires moderate temperature to accelerate the reaction.
PH adjustment: By adjusting the pH value of the reaction system, the reaction conditions are optimized. Acylation reaction requires a neutral environment, while esterification reaction requires an alkaline environment.
2. Impurity control strategy
Deacetylation impurities: By controlling the amount of base and reaction time, the hydrolysis of the 3-acetoxy group of 7-ACA is inhibited to generate deacetylation impurities.
Chloroacetamide residue: Ensure complete deprotection reaction and monitor the residual amount of chloroacetamide by HPLC to prevent drug degradation.
3. Crystal structure control and stability
Crystal form selection: By controlling the crystallization conditions and solvent ratio, obtain the highly soluble β - crystal form of cefpodoxime proxetil powder.
Stability testing: Conduct accelerated and long-term tests according to pharmacopoeia requirements to ensure the stability of the product under storage conditions.
Comparison and Prospect of Different Methods
1. Advantages and challenges of classical chemical synthesis methods
Advantages:
Mature process, high yield, easy availability of raw materials, and relatively low cost.
Challenge:
High usage of organic solvents and high cost of waste disposal; Some side reactions are difficult to completely avoid, which affects the purity of the product.
2. Potential and limitations of green synthesis routes
Potential:
Reduce the use of organic solvents and waste emissions, in line with environmental requirements; Enzyme catalysis and ionic liquid systems are expected to improve reaction selectivity and yield.
Limitations:
Green solvents and catalysts have high costs and require large-scale production to reduce costs; The process conditions need to be further optimized to improve stability and yield.
toxicology
1. Toxicity
⑴ Acute toxicity LD50 value (mg/kg)
⑵ Subacute and chronic toxicity: No abnormalities caused by this agent were observed.
2. Special toxicity
(1) Reproductive test: No abnormalities in maternal reproductive function, offspring morphology, development, growth, memory, or reproductive function caused by this agent were observed in pre pregnancy and early pregnancy drug tests, fetal organ formation drug tests, perinatal and lactation drug tests in rats.
⑵ Sperm formation inhibition test: No testicular atrophy or sperm formation inhibition effect was observed in young rats induced by this agent.
⑶ Renal toxicity: Edema and congestion were observed in the cecum of some animals in the 800 mg/kg medication group of rabbits, but no morphological changes causing renal damage were observed.
⑷ Antigenicity test: No immunogenicity was observed in all animals.
pharmacokinetics
1. Concentration in serum
When healthy adults take one or two tablets of this agent orally after meals, the highest concentration of the powder (active substance) in the serum appears 3-4 hours after administration, with concentrations of 1.5-1.8 μ g/mL and 3.0-3.6 μ g/mL, respectively, showing a dose-dependent relationship. The half-life of serum concentration does not depend on the dosage and remains constant at approximately 2 hours.
In addition, the absorption of medication after meals is better than on an empty stomach.
2. Pharmacokinetic parameters:
The absorption rate constant Ka is 0.75 ± 0.09hr-1, and the elimination rate constant Ke is 0.37 ± 0.02hr-1 (200mg orally taken by healthy adults after meals) (Mean ± S.E., n=6); Serum protein binding rate: When a person takes 200mg orally, the serum protein binding rate after 0.5-12 hours is about 30%; AUC: 8.7 ± 0.3 μ g · hr/mL (100mg orally once after meals for healthy adults) (Mean ± S.E., n=6), 15.2 ± 1.8 μ g · hr/mL (200mg orally once after meals for healthy adults) (Mean ± S.E., n=6)
3. Distribution
Distributed in sputum, tonsil tissue, skin tissue, oral tissue, etc.
4. Metabolism and excretion
This agent is hydrolyzed by intestinal wall esterase during absorption and excreted into the urine through the kidneys. The urine recovery rate within 12 hours after oral administration of cefuroxime entering the bloodstream after meals is about 40-50%. In addition, continuous administration of this agent (2 tablets x 2 times/day, for a total of 14 days) did not show any accumulation.
5. Serum concentration and urinary excretion during renal dysfunction
Mild renal dysfunction patients (Group A: 7 cases) and moderate renal dysfunction patients (Group B: 2 cases), when taking 200mg of this dose orally 30 minutes after a meal, showed an increase in Cmax, Tmax, and AUC (0-12) as renal function decreased.
The concentration of Group A in urine shows a peak at 4-6 hours, and the urine recovery rate within 12 hours is 33.8 ± 3.8%. Group B shows a peak at 8-12 hours, with a urinary recovery rate of 17.5% within 12 hours. As renal function decreases, urinary excretion is delayed.
FAQ
Is cefpodoxime proxetil a strong antibiotic?
+
-
Cefpodoxime proxetil is a moderately strong, broad-spectrum, third-generation cephalosporin antibiotic. It is a potent bactericidal medication designed to kill bacteria by destroying their cell walls. It is effective against many common Gram-positive and Gram-negative bacteria.
What to avoid when taking cefpodoxime?
+
-
While taking cefpodoxime, it is important to avoid specific medications, supplements, and lifestyle habits to ensure the antibiotic works effectively and to prevent adverse side effects.
Hot Tags: cefpodoxime proxetil powder, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale